Kymeta Broadens Network Offerings for Government and Military Through Strategic Partnership with Comtech
8.6.2021 16:00:00 EEST | Business Wire | Press release
Kymeta (kymetacorp.com), the communications company making mobile global, announced today a strategic technology partnership with Comtech EF Data Corp. (comtechefdata.com), a leading provider of satellite communication equipment. The agreement enables Kymeta to broaden its network of offerings for the Kymeta™ u8 terminal through interoperability with Comtech’s SLM-5650B modem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005043/en/
The Kymeta™ u8 GO provides a complete connectivity solution for on-the-go communications when and where you need it. (Photo: Business Wire)
The pairing of the u8 antenna and Comtech modem using the Open Antenna to Modem Interface Protocol (OpenAMIP), an industry-wide open-source standard for antenna-router integration, allows for seamless integration and automatic operation through the use of both Low Density Parity Check (“LDPC”) waveforms and STANAG 4486 Edition 3, Annex E (EBEM) waveforms.
The Comtech SLM-5650B is a U.S. Army Forces Strategic Command (ARSTRAT) Wideband Global SATCOM certified modem for critical commercial backhaul, as well as government and military applications. It is fully compliant with MIL-STD-188-165A/B, complies with and supports FIPS 140-2 certified encryption.
Kymeta u8 terminals, antennas, and ODUs are easy to set up and acquire service within minutes of installation. The u8 is also available in a transportable configuration called the u8 GO, which is ideal for rapid deployments. The u8 GO enables safe transport with a hardened case for protection and provides a built-in car mount to support easy communications on the pause (COTP) and on the move (COTM).
“The integration of the u8 antenna with the Comtech modem allows users to upgrade to a SATCOM-on-the-move (SOTM) capability while utilizing existing modem and hub architecture,” said Neville Meijers, Kymeta Chief Strategy and Marketing Officer. “The ability to leverage existing network hardware while adding the SOTM capability will rapidly enhance unit capabilities. The low SWaP-C2 of the u8 terminal also makes it a perfect choice for upgrading legacy COTM terminals.”
“Comtech is very excited to expand our solution set and capabilities offered to our government and military user base,” said Fred Kornberg, Chairman of the Board and Chief Executive Officer of Comtech Telecommunications Corp. “The engineering, development, and testing of the mobility protocols between our widely fielded SLM-5650B satellite modem and Kymeta’s state-of-the-art u8 antenna expands the range of missions we can support and further demonstrates the flexibility and long-term developmental support our government and military users expect from our products.”
Kymeta’s next-generation solutions are built for mobility and designed to meet the needs of global defense agencies, government, public safety, and commercial customers. Kymeta’s products and services have been field deployed for over three years and received an overwhelmingly positive response from the industry. Kymeta’s new products and services offer a breakthrough in performance, ease of use, and affordability, and Kymeta anticipates that these solutions will further enhance its position in both commercial and government markets, further increasing its lead over competitive offerings.
This strategic technology partnership with Comtech follows a series of recently announced relationships to further expand Kymeta solutions and trainings for government and defense agencies and its Global TRANSEC Secure Network, which is available coverage in the U.S., Middle East, and Europe. Visit www.kymetacorp.com to learn more.
About Kymeta
Kymeta is unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for comms on the move and making mobile global. Lepton Global Solutions, a Kymeta company, hosts the company’s satellite connectivity solutions and offers unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta Connect™ services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005043/en/
Contact information
Business Inquiries for Kymeta:
Brenda Kuhns
Director of Marketing and Communications
Kymeta Corporation
bkuhns@kymetacorp.com
Media Inquiries for Kymeta:
Amanda Barry
Director PR & Content
The Summit Group
abarry@summitslc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom